J9049
J9049 – Injection, bortezomib (hospira), not therapeutically equivalent to j9041 · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 2 NDCs crosswalked per 0.1 MG $1.712/unit ASP+6%
📋 J9049 summary
J9049 is a HCPCS Level II J-code used to bill bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg, billed per 0.1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9049: Bortezomib(J9049)
Code J9049
Billing unit 0.1 MG Payment limit $1.712/unit NDC-Crosswalk 2
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9049
DescriptorInjection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg
Billing unit0.1 MG
Payment limit / unit$1.712
Est. ASP / unit$1.615 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20
💊 About Bortezomib DRUG GUIDE
Bortezomib is used to treat two types of cancer in adults: multiple myeloma (a cancer of plasma cells in the bone marrow) and mantle cell lymphoma (a type of non-Hodgkin lymphoma).
These indications are shared across the available products — Velcade, Boruzu, and generic bortezomib formulations.Velcade, Boruzu, and bortezomib injections are all approved for both conditions.
Your care team will determine which product and treatment plan is right for your situation.
Clinical overview from our editorial drug guide for Bortezomib. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$1.712
Est. ASP / unit
$1.615 est.
Est. after 2% sequester
$1.678
HCPCS dosage
0.1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2023-01-01
Date added2023-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9049 = 0.1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9049 WITH EST. MEDICARE PAY
2 NDCs map to J9049. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($1.712/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00409-1703-01 | BORTEZOMIB 2.5 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Hospira, | 1 VIAL, SINGLE-DOSE in 1 CARTON (0409-1703... | 2.5 mg/1 | 25 | $42.80 | — | ● Active | CMS ASP |
| 00409-1704-01 | BORTEZOMIB 1 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Hospira, | 1 VIAL, SINGLE-DOSE in 1 CARTON (0409-1704... | 1 mg/1 | 10 | $17.12 | — | ● Active | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$6.9K
Claims
219
Beneficiaries
45
Spend / beneficiary
$152.83
Spend / claim
$31.40
Trend by period
Where J9049 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #697 of 824
#692
BLEOMYCIN SULFATE J9040
$9.1K
#693
MORPHINE SULFATE(J22... J2270
$8.2K
#694
BUPIVACAINE HCL* J0665
$8.1K
#695
MIDAZOLAM HCL J2250
$8K
#696
PFIZER COVID (6M-4... 91318
$7.4K
#697
BORTEZOMIB(J9049) J9049
$6.9K
#698
ARGATROBAN-0.9% NACL... J0883
$6.7K
#699
DIHYDROERGOTAMINE ME... J1110
$6.5K
#700
PROGRAF(J7525)* J7525
$6.4K
#701
IBANDRONATE SODIUM J1740
$6.3K
#702
LEVOLEUCOVORIN CALCI... J0641
$6.2K
Total claims — #533 of 824
#528
MODERNA COVID (6M-1... 91321
230
#529
ZYNLONTA J9359
230
#530
RENOGRAFT, PER SQ CM... Q4321
229
#531
SUBLOCADE(Q9992) Q9992
227
#532
DEXTROSE IN WATER(J7... J7070
225
#533
BORTEZOMIB(J9049) J9049
219
#534
FLOXURIDINE J9200
219
#535
AMNIOAMP-MP PER SQ C... Q4250
218
#536
AMPICILLIN SODIUM J0290
215
#537
EVKEEZA J1305
214
#538
EPIXPRESS, PER SQ CM... Q4361
212
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $6.9K | 45 | 219 | $152.83 | $31.40 |
| 2025 (Q1-Q4) | $50.6K | 157 | 1,423 | $322.54 | $35.59 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$51.4K
Medicare paid
$39.8K
Submitted services
40,140
Denial rate
10.2%
Allowed / service
$1.43
Submitted charges
$3.37M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J9049 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9049 billing FAQ
What is HCPCS code J9049?
J9049 is a HCPCS Level II J-code used to bill Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9049?
One unit of J9049 represents 0.1 MG. Report the number of units equal to the dose administered divided by 0.1 MG.
How many units of J9049 should I bill?
Divide the dose administered by the code's unit size (0.1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9049?
The Medicare Part B payment limit is $1.712 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $1.678 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9049?
2 NDCs currently map to J9049 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9049 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.